Literature DB >> 18804929

A novel POMT2 mutation causes mild congenital muscular dystrophy with normal brain MRI.

Terumi Murakami1, Yukiko K Hayashi, Megumu Ogawa, Satoru Noguchi, Kevin P Campbell, Masami Togawa, Takehiko Inoue, Akira Oka, Kousaku Ohno, Ikuya Nonaka, Ichizo Nishino.   

Abstract

We report a patient harboring a novel homozygous mutation of c.604T>G (p.F202V) in POMT2. He showed delayed psychomotor development but acquired the ability to walk at the age of 3 years and 10 months. His brain MRI was normal. No ocular abnormalities were seen. Biopsied skeletal muscle revealed markedly decreased but still detectable glycosylated forms of alpha-dystroglycan (alpha-DG). Our results indicate that mutations in POMT2 can cause a wide spectrum of clinical phenotypes as observed in other genes associated with alpha-dystroglycanopathy. Presence of small amounts of partly glycosylated alpha-DG may have a role in reducing the clinical symptoms of alpha-dystroglycanopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804929      PMCID: PMC2702532          DOI: 10.1016/j.braindev.2008.08.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  10 in total

1.  Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.

Authors:  Hiroshi Matsumoto; Yukiko K Hayashi; Dae-Son Kim; Megumu Ogawa; Terumi Murakami; Satoru Noguchi; Ikuya Nonaka; Tomoyuki Nakazawa; Takiko Matsuo; Satoshi Futagami; Kevin P Campbell; Ichizo Nishino
Journal:  Neuromuscul Disord       Date:  2005-05       Impact factor: 4.296

2.  Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness.

Authors:  Terumi Murakami; Yukiko K Hayashi; Satoru Noguchi; Megumu Ogawa; Ikuya Nonaka; Yuzo Tanabe; Mieko Ogino; Fumio Takada; Makoto Eriguchi; Norihiko Kotooka; Kevin P Campbell; Makiko Osawa; Ichizo Nishino
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

3.  Physical and functional association of human protein O-mannosyltransferases 1 and 2.

Authors:  Keiko Akasaka-Manya; Hiroshi Manya; Ai Nakajima; Masao Kawakita; Tamao Endo
Journal:  J Biol Chem       Date:  2006-05-12       Impact factor: 5.157

4.  POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.

Authors:  J van Reeuwijk; M Janssen; C van den Elzen; D Beltran-Valero de Bernabé; P Sabatelli; L Merlini; M Boon; H Scheffer; M Brockington; F Muntoni; M A Huynen; A Verrips; C A Walsh; P G Barth; H G Brunner; H van Bokhoven
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

5.  Diagnosis and etiology of congenital muscular dystrophy.

Authors:  R A Peat; J M Smith; A G Compton; N L Baker; R A Pace; D J Burkin; S J Kaufman; S R Lamandé; K N North
Journal:  Neurology       Date:  2007-12-26       Impact factor: 9.910

6.  POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes.

Authors:  Roberta Biancheri; Antonio Falace; Alessandra Tessa; Marina Pedemonte; Sara Scapolan; Denise Cassandrini; Chiara Aiello; Andrea Rossi; Paolo Broda; Federico Zara; Filippo Maria Santorelli; Carlo Minetti; Claudio Bruno
Journal:  Biochem Biophys Res Commun       Date:  2007-09-25       Impact factor: 3.575

7.  New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation.

Authors:  A Yanagisawa; C Bouchet; P Y K Van den Bergh; J-M Cuisset; L Viollet; F Leturcq; N B Romero; S Quijano-Roy; M Fardeau; N Seta; P Guicheney
Journal:  Neurology       Date:  2007-07-18       Impact factor: 9.910

8.  POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG.

Authors:  D S Kim; Y K Hayashi; H Matsumoto; M Ogawa; S Noguchi; N Murakami; R Sakuta; M Mochizuki; D E Michele; K P Campbell; I Nonaka; I Nishino
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

9.  POMT2 mutation in a patient with 'MEB-like' phenotype.

Authors:  E Mercuri; A D'Amico; A Tessa; A Berardinelli; M Pane; S Messina; J van Reeuwijk; E Bertini; F Muntoni; F M Santorelli
Journal:  Neuromuscul Disord       Date:  2006-05-15       Impact factor: 4.296

10.  Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.

Authors:  Caroline Godfrey; Emma Clement; Rachael Mein; Martin Brockington; Janine Smith; Beril Talim; Volker Straub; Stephanie Robb; Ros Quinlivan; Lucy Feng; Cecilia Jimenez-Mallebrera; Eugenio Mercuri; Adnan Y Manzur; Maria Kinali; Silvia Torelli; Susan C Brown; Caroline A Sewry; Kate Bushby; Haluk Topaloglu; Kathryn North; Stephen Abbs; Francesco Muntoni
Journal:  Brain       Date:  2007-09-18       Impact factor: 13.501

  10 in total
  4 in total

1.  Phenotype and Genotype Study of Chinese POMT2-Related α-Dystroglycanopathy.

Authors:  Xiao-Yu Chen; Dan-Yu Song; Li Jiang; Dan-Dan Tan; Yi-Dan Liu; Jie-Yu Liu; Xing-Zhi Chang; Guo-Gang Xing; Tatsushi Toda; Hui Xiong
Journal:  Front Genet       Date:  2021-08-03       Impact factor: 4.599

2.  Uniparental disomy unveils a novel recessive mutation in POMT2.

Authors:  Brianna N Brun; Tobias Willer; Benjamin W Darbro; Hernan D Gonorazky; Sergey Naumenko; James J Dowling; Kevin P Campbell; Steven A Moore; Katherine D Mathews
Journal:  Neuromuscul Disord       Date:  2018-04-10       Impact factor: 4.296

3.  Biochemical correlation of activity of the α-dystroglycan-modifying glycosyltransferase POMGnT1 with mutations in muscle-eye-brain disease.

Authors:  Josef Voglmeir; Sara Kaloo; Nicolas Laurent; Marco M Meloni; Lisa Bohlmann; Iain B H Wilson; Sabine L Flitsch
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

4.  Structure of the eukaryotic protein O-mannosyltransferase Pmt1-Pmt2 complex.

Authors:  Lin Bai; Amanda Kovach; Qinglong You; Alanna Kenny; Huilin Li
Journal:  Nat Struct Mol Biol       Date:  2019-07-08       Impact factor: 15.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.